Post by
prophetoffactz on Jun 06, 2024 8:03am
New name, new website, new plan, new data, new developments
New name expected in coming weeks.
That will support a new website.
AGM in July with everyone in their new positions.
There should be a new plan with prioritized assets.
The company is reviewing its assets and prioritizing them as it streamlines both companies.
The diagnostic top-llne data is expected in Q3 making way for potential regulatory submission and a licensing deal or will AEZS go it alone. Does the childhood market offer a new distribution strategy?
Avenanthramide single-ascending dose data could be released at any time making way for the multi-ascending dose portion of the clinical trial expected in the summer.
The fine-tuning of the 50L PGX scale-up could be completed at any time and PGX-YBG submitted to Health Canada for potential approval of the first PGX product later this year.
The 100L PGX scale-up is expected to be commissioned in Q3 with industry leader NATEX. The 100L facility is the decision point for mass industrialization of PGX.
The 50L facility was expected to provide materials for potential partners. With Health Canada approval of the first PGX product and the decision point for mass industrialization of PGX having been reached will there be a PGX licensing deal or partnership?
In CZO's November news release an animal trial protocol was said developed for PGX-YBG as an immune booster. Could results further support AEZS as having the emerging gold standard?
The PGX-YBG/fibrosis data is pending potential publication in the journal Biomaterials and Dr. Martin Kolb previously said that if preclinical results are replicated in humans it could profoundly change the treatment landscape.
The new Angiogenesis Foundation wound healing data should be nearing completion and Gilles called the previous data a 'home run'. The gold standard animal model other companies use was used.
The chewy beta glucan was expected to be launched in the second half of the year. What is the plan?
A major potential client was evaluating the avenanthramide malted technology as Symrise evaluates powder beta glucan.
AEZS expected NMSOD data from Harvard very soon about eight months ago. Harvard is an authority in this area and its models have been used for other products.
The hypothyroidism product was also being further developed.
Talks concerning the future regulatory path for AEZS's multi-billion dollar potential pipeline were expected near term. Are human studies now in site?
AEZS's news release:
Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”